These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22335400)

  • 21. Involvement of cannabinoid receptors in gut motility and visceral perception.
    Hornby PJ; Prouty SM
    Br J Pharmacol; 2004 Apr; 141(8):1335-45. PubMed ID: 15100166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity.
    McLaughlin PJ
    Behav Pharmacol; 2012 Sep; 23(5-6):537-50. PubMed ID: 22743603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
    Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK
    J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.
    Higgins GA; Sellers EM; Fletcher PJ
    Trends Pharmacol Sci; 2013 Oct; 34(10):560-70. PubMed ID: 24041919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of the endocannabinoid system in drug addiction.
    Maldonado R; Valverde O; Berrendero F
    Trends Neurosci; 2006 Apr; 29(4):225-32. PubMed ID: 16483675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
    Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
    J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
    Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C
    Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.
    Fong TM; Heymsfield SB
    Int J Obes (Lond); 2009 Sep; 33(9):947-55. PubMed ID: 19597516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation.
    Debenham JS; Madsen-Duggan CB; Wang J; Tong X; Lao J; Fong TM; Schaeffer MT; Xiao JC; Huang CC; Shen CP; Sloan Stribling D; Shearman LP; Strack AM; Euan Macintyre D; Hale JJ; Walsh TF
    Bioorg Med Chem Lett; 2009 May; 19(9):2591-4. PubMed ID: 19328684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.
    Janero DR; Thakur GA
    Expert Opin Drug Discov; 2016 Dec; 11(12):1223-1237. PubMed ID: 27712124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocannabinoid system--a novel target for cardiometabolic risk.
    Joshi SR
    J Assoc Physicians India; 2007 Jun; 55():439-44. PubMed ID: 17879500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The therapeutic potential of second and third generation CB
    Cinar R; Iyer MR; Kunos G
    Pharmacol Ther; 2020 Apr; 208():107477. PubMed ID: 31926199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
    Zhu B; Matthews JM; Xia M; Black S; Chen C; Hou C; Liang Y; Tang Y; Macielag MJ
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5597-5601. PubMed ID: 27671499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel pyrazole derivatives as neutral CB₁ antagonists with significant activity towards food intake.
    Manca I; Mastinu A; Olimpieri F; Falzoi M; Sani M; Ruiu S; Loriga G; Volonterio A; Tambaro S; Bottazzi ME; Zanda M; Pinna GA; Lazzari P
    Eur J Med Chem; 2013 Apr; 62():256-69. PubMed ID: 23357307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist.
    Muller T; Demizieux L; Troy-Fioramonti S; Buch C; Leemput J; Belloir C; Pais de Barros JP; Jourdan T; Passilly-Degrace P; Fioramonti X; Le Bon AM; Vergès B; Robert JM; Degrace P
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of type 1 cannabinoid receptor allosteric ligands.
    Alaverdashvili M; Laprairie RB
    Drug Metab Rev; 2018 Feb; 50(1):14-25. PubMed ID: 29355038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications.
    Nagappan A; Shin J; Jung MH
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight.
    Engeli S
    Handb Exp Pharmacol; 2012; (209):357-81. PubMed ID: 22249824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
    Laprairie RB; Kulkarni PM; Deschamps JR; Kelly MEM; Janero DR; Cascio MG; Stevenson LA; Pertwee RG; Kenakin TP; Denovan-Wright EM; Thakur GA
    ACS Chem Neurosci; 2017 Jun; 8(6):1188-1203. PubMed ID: 28103441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic Profiling of CB1 Neutral Antagonists.
    Seltzman HH; Maitra R; Bortoff K; Henson J; Reggio PH; Wesley D; Tam J
    Methods Enzymol; 2017; 593():199-215. PubMed ID: 28750803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.